內地房地產融資白名單加速擴容 據報逾30間房企項目入圍
內地房地產項目白名單加速擴容,《上海證券報》報道,截至本月19日,金科股份(000656.SZ)、碧桂園(02007.HK)、奧園集團等30多家房企項目已入圍白名單,部分項目的燃眉之急得以緩解。
其中,碧桂園截至本月15日,集團旗下已有272個項目被納入白名單,分佈於全國25個省份,已獲融資支持金額17.32億元人民幣;金科股份已有75個項目入圍,涉及重慶、河南、山東、廣西、湖北、遼寧等地。
報道指,房地產項目白名單擴容與落地,對房企項目建設及按時交付是重大利好。接近奧園集團的人士指,入選白名單的項目不斷增加,對完成年內保交樓任務具有信心,截至本月12日,奧園超過九成項目實現復工復產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.